ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI's stock price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.62 and traded as low as $1.52. ESSA Pharma shares last traded at $1.58, with a volume of 81,023 shares changing hands.
ESSA Pharma Trading Down 1.4 %
The stock's fifty day moving average price is $1.62 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $77.46 million, a price-to-earnings ratio of -2.53 and a beta of 1.61.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01). Analysts anticipate that ESSA Pharma Inc. will post -0.42 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new position in shares of ESSA Pharma during the fourth quarter worth about $44,000. Magnus Financial Group LLC acquired a new position in shares of ESSA Pharma in the 4th quarter valued at $99,000. BML Capital Management LLC purchased a new stake in shares of ESSA Pharma in the fourth quarter valued at about $7,557,000. Lepercq Multi Asset Fund purchased a new stake in ESSA Pharma during the 4th quarter valued at approximately $54,000. Finally, Aldebaran Capital LLC purchased a new stake in shares of ESSA Pharma during the fourth quarter worth approximately $712,000. Institutional investors and hedge funds own 75.12% of the company's stock.
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
